1.92
price up icon1.05%   0.02
after-market アフターアワーズ: 1.95 0.03 +1.56%
loading
前日終値:
$1.90
開ける:
$1.92
24時間の取引高:
955
Relative Volume:
0.02
時価総額:
$92.33M
収益:
$18.11M
当期純損益:
$-18.95M
株価収益率:
-4.3886
EPS:
-0.4375
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+0.79%
6か月 パフォーマンス:
-2.04%
1年 パフォーマンス:
-37.76%
1日の値動き範囲:
Value
$1.92
$1.92
1週間の範囲:
Value
$1.90
$1.98
52週間の値動き範囲:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
名前
Adagene Inc Adr
Name
セクター
Healthcare (1174)
Name
電話
-
Name
住所
-
Name
職員
138
Name
Twitter
Name
次回の収益日
2024-03-28
Name
最新のSEC提出書
Name
ADAG's Discussions on Twitter

ADAG を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ADAG
Adagene Inc Adr
1.92 92.33M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-31 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-06-25 開始されました China Renaissance Buy
2021-03-08 開始されました Goldman Buy
2021-03-08 開始されました Jefferies Buy
2021-03-08 開始されました Morgan Stanley Overweight

Adagene Inc Adr (ADAG) 最新ニュース

pulisher
Jun 14, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jun 14, 2025
pulisher
Jun 03, 2025

Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama

Jun 02, 2025
pulisher
May 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 27, 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

May 23, 2025
pulisher
May 22, 2025

Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks

May 22, 2025
pulisher
May 22, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan

May 22, 2025
pulisher
Apr 30, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan

Apr 28, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire

Apr 23, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan

Apr 07, 2025
pulisher
Apr 07, 2025

FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World

Apr 07, 2025
pulisher
Apr 05, 2025

Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 05, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 25, 2025

Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne

Mar 12, 2025
pulisher
Mar 07, 2025

Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 06, 2025

Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan

Feb 27, 2025
pulisher
Feb 23, 2025

Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat

Feb 16, 2025
pulisher
Feb 13, 2025

Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World

Feb 13, 2025
pulisher
Feb 04, 2025

Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat

Feb 01, 2025

Adagene Inc Adr (ADAG) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
大文字化:     |  ボリューム (24 時間):